**Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial - A preliminary report.**

**Supplementary appendix**

**Table of contents**

[**Methods** 2](#_Toc48142844)

[**Sequential monitoring and early stopping** 2](#_Toc48142845)

[**Protocol Changes** 2](#_Toc48142846)

[**Supplementary tables.** 5](#_Toc48142847)

[**Table S1. Summary of changes made to trial protocol.** 5](#_Toc48142848)

[**Table S2. Occurrence of ICU admission, mechanical ventilation, death and composite outcome by treatment group.** 8](#_Toc48142849)

[**Table S3. Patients characteristics and causes of death.** 9](#_Toc48142850)

[**Table S4. Blood pressure of enrolled patients at day 1, day 5 and day 8 after randomization by treatment group.** 10](#_Toc48142851)

[**Table S5. Hematological indices at day 5 and 8 by treatment group.** 11](#_Toc48142852)

[**Supplementary figures** 12](#_Toc48142853)

[**Figure S1. Biochemical and hematological indices at days 1, 5 and 8 by treatment group** 12](#_Toc48142854)

[**Supplementary references** 13](#_Toc48142855)

# **Methods**

## **Sequential monitoring and early stopping**

Outcomes will be monitored throughout the trial and used for interim analyses of efficacy and safety.

A first interim analysis will be conducted on July 31st 2020; due to the lack of vaccine and effective treatments at the time of writing of this protocol and the urgent public health situation, we have planned this first analysis not based on the number of patients enrolled but at 2 and a half months from initial recruitment.

A second interim analysis is planned to be conducted when a total of 140 patients are recruited. Although our estimated sample size was 390, it is worth noticing that this number accounts for a scale factor on both the mean and the variability estimations; without these factors, the estimated sample size was 52 patients total, and with only a variability factor of 2 the total estimated number was 100. Therefore, we evaluate that, if our original mean and variability assessments are correct or only slightly deviated, efficacy can be conservative appraised with 140 patients in total.

A third interim analysis will be conducted when 200 patients total are recruited (half of our estimated sample size).

Early stopping due to efficacy is defined as achieving significant differences between groups in our main outcome. To control across repeated analyses for Type I error, set at 0.05, critical values for interim testing will be defined based on O'Brien-Fleming’s boundaries. With this approach, interim tests early in the trial are conservative and the reduction in the overall power of the trial caused by interim testing is small. These boundaries will not be used for safety outcomes.

## **Protocol Changes**

Original design of the protocol included only one center of enrollment (site 1, Hospital de Clínicas “Jose de San Martin” [HCJSM]). The first amendment to protocol was made to include enrolment on a second site (site 2, Hospital Español de Buenos Aires [HEBA]). Approvals from Ethics Committee at HCJSM and IRB at HEBA were obtained.

Second amendment to protocol was made to change primary outcome, which was set originally to detect significative reductions in C-reactive protein (CRP) serum levels at days 8 and 15 after randomization. Reports made after the writing of the original version of the protocol as well as observations made by the research team showed that CRP levels may fall rapidly in recovering patients[1](#_ENREF_1),[2](#_ENREF_2). Therefore, original endpoint measuring CRP levels at day 15 after randomization was replaced by an earlier timepoint at day 5 to better capture the dynamic of CRP changes and its potential modification by telmisartan treatment. Additional support of this change was brought by the length of stay of patients which often was shorter than 15 days, leading to an excessive amount of missing data. Although changes in the primary outcome are not common for diseases that are well understood, it is recognized that in some trials, such as those involving poorly understood diseases, circumstances may require a change in the way an outcome is assessed or may necessitate a different outcome[3](#_ENREF_3).

Initial protocol design included: Number of opacified quadrants on lung Rx [Time Frame: Days 1, 8 and 15 after enrollment], Significative differences in troponin T positivity [Time Frame: Days 5, 8 and 15 after enrollment] and Time to mechanical ventilation [Time Frame: Within 15 days]. Logistical and infrastructure limitations precluded obtention of lung Rx at days 8 and 15. Additionally, troponin T determination was not available for days 8 and 15 and therefore was excluded as an endpoint. Also, to more appropriately quantify the rate of improvement in both groups, time to discharge and proportion of patients not requiring supplemental oxygen at day 15 were included. Finally, a composite endpoint of mechanical ventilation, intensive care unit admission and death was added to better quantify treatment effect.

Admission to intensive care unit (ICU) prior to randomization was added as an exclusion criterion after initial enrolment. No patients were enrolled while being in ICU. Also, initial patient enrolment showed a short time between onset of symptoms and randomization at site 1 (Hospital de Clínicas). Therefore, to reduce inter site variability, a new exclusion criterion was added, precluding participation in patients with symptom onset more than 4 days prior to randomization. Protocol changes are summarized in table S1.

# **Supplementary tables.**

## **Table S1. Summary of changes made to trial protocol.**

|  |  |
| --- | --- |
| First version | Final Version |
| Primary outcome |
| C reactive protein  | C reactive protein  |
| Serum C reactive protein levels  | Serum C reactive protein levels  |
| [Time Frame: Days 8 and 15 after enrollment] | [Time Frame: Days 5 and 8 after enrollment] |
|
| Secondary outcome |
| Admission to intensive care unit | Admission to intensive care unit |
| [Time Frame: Within 15 days after randomization] | [Time Frame: Within 15 and 30 days after randomization] |
|
|
| Occurrence of mechanical ventilation  | Occurrence of mechanical ventilation  |
| [Time Frame: Within 15 days after randomization] | [Time Frame: Within 15 and 30 days after randomization] |
| Death  | Death  |
| All-cause mortality | All-cause mortality |
| [Time Frame: Within 15 days, 30 days, 90 days] | [Time Frame: Within 15 days and 30 days] |
|
| Number of opacified quadrants on lung Rx  | Removed |
|
| [Time Frame: Days 1, 8 and 15 after enrollment] |
|
| Time to mechanical ventilation  | Removed |
| Within 15 days |
| LDH  | LDH  |
| Lactate dehydrogenase serum levels  | Lactate dehydrogenase serum levels  |
| [Time Frame: Days 1, 8 and 15 after enrollment] | [Time Frame: Days 5 and 8 after enrollment] |
| Troponin  | Removed |
| Troponin serum levels  |
| [Time Frame: Days 1, 8 and 15 after enrollment] |
|  | Composite occurrence of admission to ICU, mechanical ventilation or death (what occur first)  |
|  | [Time Frame: Within 15 and 30 days after randomization]  |
|  | Proportion of patients not requiring supplemental oxygen at day 15  |
|  | [Time Frame: Within 15]  |
|  | Time from randomization to discharge  |
|  | [Time Frame: Within 15 days]  |
| Other measures |
| Active urinary sediment  | Removed |
| Normal/abnormal  |
| [Time Frame: Days 1, 8 and 15 after enrollment] |
|
| Inclusion Criteria: |
|   | Aged 18 years or older |
| Aged 18 years or older | Confirmed diagnosis of COVID-19 by PCR test |
| Confirmed diagnosis of COVID-19 by PCR test | Hospitalization for COVID-19 |
|   | Illness symptoms beginning 4 days or less prior to randomization |
| Exclusion Criteria: |
| Hospitalization in the previous 6 months |  |
| Pregnancy | Pregnancy |
| Breast feeding | Breast feeding |
| Major allergy to any AT1 receptor blocker | Major hypersensibility to angiotensin receptor blockers (ARBs) |
| Systolic arterial pressure lower than 100 mmHg | Systolic blood pressure < 100mmHg |
| Serum potassium higher than 5.5 mEq/l | Potassium greater than 5.5 mEq/L |
| AST/ALT higher than 3x normal | AST and/or ALT > 3 times the upper limit of normal |
| Serum Creatinine higher than 3 mg/dl. | Serum creatinine higher than 3 mg/dL |
| Patient is taking ACEi or ARB. | Current treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB |
|   | Admitted to ICU prior to randomization |
|   | Illness symptoms beginning more than 4 days prior to randomization |

## **Table S2. Occurrence of ICU admission, mechanical ventilation, death and composite outcome by treatment group.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | ICU admission | Mechanical ventilation | Death | ICU admission, mechanical ventilation and death. |
| Group | Within day 15 | Within day 30 | Within day 15 | Within day 30 | Within day 15 | Within day 30 | Within day 15 | Within day 30 |
| Control (n) | 5 | 5 | 3 | 3 | 2 | 4 | 7 | 9 |
| Telmisartan (n) | 4 | 4 | 1 | 1 | 2 | 2 | 6 | 6 |

## **Table S3. Patients characteristics and causes of death.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Patient id | Group | Severity at admission | Age | Comorbidities | Days after randomization | Cause of death |
| 17 | Control | No need of supplemental O2 | 84 | None | 22 days | sepsis |
| 18 | Control | Need of supplemental O2 | 75 | Hypertension | 10 days | respiratory insufficiency |
| 35 | Control | Need of supplemental O2 | 94 | Cognitive impairment | 27 days | respiratory insufficiency |
| 61 | Control | Need of supplemental O2 | 81 | Hypertension, stroke, cognitive impairment | 13 days | respiratory insufficiency |
| 39 | telmisartan | Need of high flow supplemental O2 | 69 | Hypertension, stroke, peripheral vascular disease, heart failure, arrythmia. | 4 days | fulminant myocarditis |
| 40 | telmisartan | No need of supplemental O2 | 89 | Dyslipemia, stroke, arrythmia, peripheral vascular disease. | 15 days | sepsis |

## **Table S4. Blood pressure of enrolled patients at day 1, day 5 and day 8 after randomization by treatment group.**

|  |
| --- |
| Blood pressure |
|  | Day 1 | Day 5 | Day 8 |
|  | SystolicMean ± SD (n) | DiastolicMean ± SD (n) | SystolicMean ± SD (n) | DiastolicMean ± SD (n) | SystolicMean ± SD (n) | DiastolicMean ± SD (n) |
| Control | 120.5 ± 18.2 (37) | 71.6±9.7 (37) | 119.0 ± 12.1 (33) | 70.4±7.1 (33) | 118.1±16.6 (24) | 70.6±10.7 (24) |
| Telmisartan | 121.3±12.8 (40) | 72.6±10.6 (40) | 118.7±12.1 (38) | 70.4±7.7 (38) | 115.0±15.4 (22) | 69.5±10.0 (22) |

## **Table S5. Hematological indices at day 5 and 8 by treatment group.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Day | Control(mean ± SD, [n]) | telmisartan(mean ± SD, [n]) | mean difference (95 % CI) |
| White blood cell count (103/µL) | Day 5 | 6.56 ± 2.72 [28] | 6.73 ± 2.88 [31] | -0.17 (-1.97 to 1.62) |
| Day 8 | 7.91 ± 2.73 [16] | 5.72 ± 1.59 [13] | 2.20 (0.12 to 4.28) |
| Lymphocyte count (103/µL) | Day 5 | 1.32 ± 0.86 [28] | 1.72 ± 0.81 [29] | -0.39 (-0.94 to 0.15) |
| Day 8 | 1.28 ± 0.92 [13] | 1.75 ± 0.74 [13] | -0.48 (-1.32 to 0.36) |
| Neutrophil count (103/µL) | Day 5 | 4.61 ± 2.67 [28] | 4.53 ± 3.07 [29] | 0.088 (-1.79 to 1.96) |
| Day 8 | 5.87 ± 2.71 [13] | 3.07 ± 1.72 [13] | 2.80 (0.48 to 5.12) |
| Neutrophil to lymphocyte ratio | Day 5 | 5.19 ± 6.33 [28] | 4.12 ± 5.12 [29] | 1.07 (-2.70 to 4.84) |
| Day 8 | 6.69 ± 5.63 [13] | 2.31 ± 2.67 [13] | 4.34 (-0.19 to 8.95) |
| Eosinophil count (103/µL) | Day 5 | 0.056 ± 0.07 [27] | 0.099 ± 0.136 [29] | -0.04374 (-0.1147 to 0.02723) |
| Day 8 | 0.159 ± 0.167 [13] | 0.135 ± 0.108 [13] | 0.024 (-0.119 to 0.167) |
| Platelets count(103/µL) | Day 5 | 235.9 ± 96.1 [28] | 305 ± 144.9 [31] | -69.59 (-147.90 to 8.68) |
| Day 8 | 315.4 ± 101.3 [16] | 321.3 ± 124.1 [13] | -5.87 (-115.8 to 104.1) |

The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.

# **Supplementary figures**

# **Figure S1. Biochemical and hematological indices at days 1, 5 and 8 by treatment group**

Lactate dehydrogenase (LDH, a), white blood cells (WBC, b), neutrophils (c), lymphocytes (d), neutrophil to lymphocyte ratio (e), eosinophils (f) and platelets (g) at days 1, 5 and 8 in control (black) and telmisartan (red) groups. All points represent mean ± SEM.

# **Supplementary references**

1. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. 2020;92:856-62.

2. Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. J Med Virol 2020;69:599-606.

3. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.